{
  "docId": "019de076-3901-734c-833f-b5b0e2d3aa41",
  "docSlug": "e86c5f257c7f518e1f9c16c922f96c7d",
  "documentTitle": "Exscientia | Investor Presentation Deck | 76 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 74,
  "pageCount": 76,
  "prevPage": 73,
  "nextPage": 75,
  "slideType": "other",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a two-column layout to contrast PK data with Toxicology/Safety data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-3901-734c-833f-b5b0e2d3aa41/74",
  "deckHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41",
  "deckJsonHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41.json",
  "deckAnchorHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41#slide-74",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.395,
        "x": 0.523,
        "y": 0.325
      },
      "kind": "list",
      "text": "Toxicology & Safety Pharmacology\nNo unexpected in vitro or in vivo safety concerns identified for a patient trial\nWell tolerated in rat/dog dose range finding (DRF) studies\nGLP toxicology studies completed and identified a suitable NOAEL enabling clinical trials",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a7240ab7-7a81-4125-8992-234833257402",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.395,
        "x": 0.086,
        "y": 0.325
      },
      "kind": "list",
      "text": "Pharmacokinetics (PK)\nExcellent PK across preclinical species\nLow predicted human clearance and high oral bioavailability\nHuman clearance data suggests a half-life consistent with QD dosing\nLow UGT1A1-mediated DDI risk (differentiated vs other compounds) leading to potentially better safety (hyperbilirubinaemia) profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f65e6d29-a7e4-4390-a0d2-410b9e0bbdad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.685,
        "x": 0.076,
        "y": 0.143
      },
      "kind": "title",
      "text": "Favourable PK, toxicology & safety pharm in preclinical species",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d143ad11-910f-4743-85e1-c83f50597f8d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.125,
        "x": 0.076,
        "y": 0.068
      },
      "kind": "title",
      "text": "MALT1",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef71cae7-d5cd-4fa9-a8ec-794ee53500b0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "811158fc-fb7e-43b3-b5b5-f629d803c9a4",
      "evidence": "The slide contains a list/bullet points with pharmacokinetics (PK) and toxicology & safety pharmacology data.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}